Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. This Business Profile tracks the Brand Authority Index and supporting AI visibility evidence. Last analyzed August 23, 2026.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a longitudinal, multi-center, observational study. Its overall goal is to validate biomarkers for Alzheimer’s disease (AD) clinical trials and share comprehensive research data and biospecimens with the global scientific community.
AI did not recommend this brand in the limited public category test.
Optimly has not yet published a supported competitor set for ADNI (Alzheimer's Disease Neuroimaging Initiative).
Brand Authority Index (BAI) tier: Emerging (exact score locked for unclaimed brands)
Official website: https://adni.loni.usc.edu/
Last analyzed: August 23, 2026
This Business Profile is published by Optimly in the Optimly AI Brand Index, a public research dataset showing how AI systems describe brands, categories, and competitors. Optimly AI Visibility analyzes sampled buyer-intent responses, cited sources, and public brand information. The Brand Authority Index summarizes answer presence, narrative accuracy, and owned citations where sufficient evidence is available.
If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile